JP2018516854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516854A5 JP2018516854A5 JP2017552058A JP2017552058A JP2018516854A5 JP 2018516854 A5 JP2018516854 A5 JP 2018516854A5 JP 2017552058 A JP2017552058 A JP 2017552058A JP 2017552058 A JP2017552058 A JP 2017552058A JP 2018516854 A5 JP2018516854 A5 JP 2018516854A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoconjugate
- nanoparticles
- composition
- antibody fragment
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144278P | 2015-04-07 | 2015-04-07 | |
| US62/144,278 | 2015-04-07 | ||
| US201562151943P | 2015-04-23 | 2015-04-23 | |
| US62/151,943 | 2015-04-23 | ||
| PCT/US2016/026434 WO2016164578A1 (en) | 2015-04-07 | 2016-04-07 | Nanoparticle immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021014331A Division JP7016975B2 (ja) | 2015-04-07 | 2021-02-01 | ナノ粒子イムノコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516854A JP2018516854A (ja) | 2018-06-28 |
| JP2018516854A5 true JP2018516854A5 (https=) | 2019-05-09 |
| JP6869187B2 JP6869187B2 (ja) | 2021-05-12 |
Family
ID=55806803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552058A Active JP6869187B2 (ja) | 2015-04-07 | 2016-04-07 | ナノ粒子イムノコンジュゲート |
| JP2021014331A Active JP7016975B2 (ja) | 2015-04-07 | 2021-02-01 | ナノ粒子イムノコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021014331A Active JP7016975B2 (ja) | 2015-04-07 | 2021-02-01 | ナノ粒子イムノコンジュゲート |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10548989B2 (https=) |
| EP (1) | EP3280454A1 (https=) |
| JP (2) | JP6869187B2 (https=) |
| KR (1) | KR102701678B1 (https=) |
| CN (2) | CN113876962A (https=) |
| AU (2) | AU2016246737B2 (https=) |
| CA (1) | CA2980462C (https=) |
| HK (1) | HK1250646A1 (https=) |
| WO (1) | WO2016164578A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161734B2 (en) | 2009-07-02 | 2024-12-10 | Sloan-Kettering Institute For Cancer Research | Multimodal silica-based nanoparticles |
| EP2968621B1 (en) | 2013-03-15 | 2022-08-10 | Memorial Sloan-Kettering Cancer Center | Multimodal silica-based nanoparticles |
| CA2980462C (en) | 2015-04-07 | 2023-08-01 | The Curators Of The University Of Missouri | Nanoparticle immunoconjugates |
| JP6974178B2 (ja) | 2015-05-29 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | フェロトーシスを介して栄養欠乏がん細胞の細胞死を誘導するための極小ナノ粒子を使用する処置方法 |
| CN109069666B (zh) | 2016-04-29 | 2023-04-04 | 纪念斯隆凯特琳癌症中心 | 使靶向颗粒穿透、分布和响应于恶性脑肿瘤中的组合物和方法 |
| BR112019000143A2 (pt) | 2016-07-07 | 2019-04-16 | Memorial Sloan Kettering Cancer Center | sistemas de imagem e métodos para radiogenomia de câncer conduzido por partícula, baseado no conhecimento e preditivo |
| EP3548096B1 (en) | 2016-11-30 | 2024-11-20 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| KR102228571B1 (ko) * | 2017-02-09 | 2021-03-16 | 주식회사 메디폴리머 | 정신질환 또는 중추신경계 질환 치료용 약물전달 제형 |
| CA3064253A1 (en) * | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof |
| MX2020007306A (es) * | 2018-01-12 | 2020-09-25 | Prolynx Llc | Tratamiento sinergico de cancer. |
| JP7551110B2 (ja) * | 2018-04-06 | 2024-09-17 | ノース カロライナ ステート ユニバーシティ | 癌免疫療法のためのチェックポイント阻害剤の細胞集団を介した送達 |
| EP3811054A1 (en) * | 2018-06-21 | 2021-04-28 | Codiak BioSciences, Inc. | Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering |
| CA3115355A1 (en) | 2018-10-16 | 2020-04-23 | Silicycle Inc. | Tunable process for silica capsules/spheres preparation and their use |
| CN109490523A (zh) * | 2018-10-22 | 2019-03-19 | 北京纳晶生物科技有限公司 | 用于标记的纳米材料、核酸探针及核酸与纳米材料偶联的方法 |
| KR102336120B1 (ko) * | 2019-06-05 | 2021-12-08 | 주식회사 엔이에스바이오테크놀러지 | 금 나노입자-앱타머 결합체를 기반으로 하는 항체 전달체 및 이의 제조 방법 |
| CN114667162A (zh) | 2019-09-16 | 2022-06-24 | Abk生物医学公司 | 放射性微粒和非放射性微粒的组合物 |
| WO2021054490A1 (ko) * | 2019-09-18 | 2021-03-25 | 연세대학교 산학협력단 | 양친매성 고분자, 이를 포함하는 수분산성 금속나노입자 및 이의 제조방법 |
| CN114929281A (zh) * | 2019-11-04 | 2022-08-19 | 康奈尔大学 | 超小型纳米颗粒及其制备、使用和分析方法 |
| WO2021222759A1 (en) * | 2020-04-30 | 2021-11-04 | Board Of Regents, The University Of Texas System | Albumin drug conjugates and use thereof for the treatment of cancer |
| CN111906328B (zh) * | 2020-08-11 | 2022-10-25 | 苏州大学 | 一种177Lu标记的金纳米团簇及其制备方法和应用 |
| WO2022093800A2 (en) | 2020-10-27 | 2022-05-05 | Elucida Oncology, Inc. | Carrier particle-drug conjugates, self-immolative linkers, and uses thereof |
| WO2025178318A1 (ko) * | 2024-02-20 | 2025-08-28 | 주식회사 심비스타 | Nmda 수용체 항체 및 형광물질을 포함하는 신규 테라그노스틱 나노복합체 및 이것의 용도 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| SI2371392T1 (sl) | 2002-05-02 | 2015-10-30 | Wyeth Holdings Llc | Konjugati derivat-nosilec kaliheamicina |
| WO2003097647A1 (en) | 2002-05-15 | 2003-11-27 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
| US20040101822A1 (en) * | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| US20060222595A1 (en) * | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| US20100183504A1 (en) * | 2007-06-14 | 2010-07-22 | Fanqing Frank Chen | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
| US20080317768A1 (en) * | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
| KR101662622B1 (ko) * | 2007-10-04 | 2016-10-05 | 지모제넥틱스, 인코포레이티드 | Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법 |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| WO2010060217A1 (en) * | 2008-11-26 | 2010-06-03 | National Research Council Of Canada | Antibody-targeted carrier for contrast agents |
| EP3912643B8 (en) | 2009-02-13 | 2023-08-23 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| WO2011003109A1 (en) | 2009-07-02 | 2011-01-06 | Sloan-Kettering Institute For Cancer Research | Fluorescent silica-based nanoparticles |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| JP2013534931A (ja) * | 2010-04-15 | 2013-09-09 | オリガシス | 高分子量双性イオン含有重合体 |
| EP2968621B1 (en) | 2013-03-15 | 2022-08-10 | Memorial Sloan-Kettering Cancer Center | Multimodal silica-based nanoparticles |
| CA2980462C (en) * | 2015-04-07 | 2023-08-01 | The Curators Of The University Of Missouri | Nanoparticle immunoconjugates |
| CA3064253A1 (en) * | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof |
-
2016
- 2016-04-07 CA CA2980462A patent/CA2980462C/en active Active
- 2016-04-07 EP EP16718099.1A patent/EP3280454A1/en active Pending
- 2016-04-07 JP JP2017552058A patent/JP6869187B2/ja active Active
- 2016-04-07 US US15/564,315 patent/US10548989B2/en active Active
- 2016-04-07 KR KR1020177031663A patent/KR102701678B1/ko active Active
- 2016-04-07 WO PCT/US2016/026434 patent/WO2016164578A1/en not_active Ceased
- 2016-04-07 HK HK18110131.9A patent/HK1250646A1/zh unknown
- 2016-04-07 CN CN202111317319.3A patent/CN113876962A/zh active Pending
- 2016-04-07 CN CN201680024624.4A patent/CN107735110B/zh active Active
- 2016-04-07 AU AU2016246737A patent/AU2016246737B2/en active Active
-
2019
- 2019-11-26 AU AU2019271919A patent/AU2019271919B2/en active Active
- 2019-12-19 US US16/720,176 patent/US20200353096A1/en not_active Abandoned
-
2021
- 2021-02-01 JP JP2021014331A patent/JP7016975B2/ja active Active
-
2022
- 2022-10-07 US US17/961,761 patent/US20230037294A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516854A5 (https=) | ||
| Wu et al. | Radioactive polymeric nanoparticles for biomedical application | |
| Majkowska-Pilip et al. | Nanoparticles in targeted alpha therapy | |
| Dekempeneer et al. | Therapeutic efficacy of 213Bi-labeled sdAbs in a preclinical model of ovarian cancer | |
| Boswell et al. | Effects of charge on antibody tissue distribution and pharmacokinetics | |
| Wängler et al. | Antibody− dendrimer conjugates: The number, not the size of the dendrimers, determines the immunoreactivity | |
| JP2025013502A (ja) | 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法 | |
| Cohen et al. | Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling | |
| Pant et al. | Radiolabelled polymeric materials for imaging and treatment of cancer: quo vadis? | |
| JP6869187B2 (ja) | ナノ粒子イムノコンジュゲート | |
| Etrych et al. | Targeted drug delivery and theranostic strategies in malignant lymphomas | |
| Azadbakht et al. | Preparation and evaluation of APTES-PEG coated iron oxide nanoparticles conjugated to rhenium-188 labeled rituximab | |
| CA2986699A1 (en) | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting | |
| Aranda‐Lara et al. | Drug Delivery Systems‐Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy | |
| DE60320398T2 (de) | Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs | |
| Trencsényi et al. | Targeted radium alpha therapy in the era of nanomedicine: in vivo results | |
| Adumeau et al. | Site-specific, platform-based conjugation strategy for the synthesis of dual-labeled immunoconjugates for bimodal PET/NIRF imaging of HER2-positive tumors | |
| Warnders et al. | Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds | |
| Polyak et al. | Preparation and 68Ga-radiolabeling of porous zirconia nanoparticle platform for PET/CT-imaging guided drug delivery | |
| TWI908815B (zh) | 用於人類疾病之治療的ｃｄ３８抗體 | |
| Wang et al. | Ultrasmall gold nanoparticles radiolabeled with iodine-125 as potential new radiopharmaceutical | |
| Jimenez-Mancilla et al. | Multifunctional targeted radiotherapy system for induced tumours expressing gastrin-releasing peptide receptors | |
| Misri et al. | Evaluation of 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors | |
| CN102065906B (zh) | 放射性标记大分子的方法 | |
| CN107690334A (zh) | 使用针对haah的抗体对癌症的放射成像和放射治疗 |